RxSight (RXST) Competitors $31.90 -0.29 (-0.90%) Closing price 02/12/2025 04:00 PM EasternExtended Trading$31.16 -0.74 (-2.34%) As of 02/12/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RXST vs. NARI, NVST, PRCT, IRTC, WRBY, LIVN, ENOV, TMDX, NVCR, and TNDMShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Inari Medical (NARI), Envista (NVST), PROCEPT BioRobotics (PRCT), iRhythm Technologies (IRTC), Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), TransMedics Group (TMDX), NovoCure (NVCR), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry. RxSight vs. Inari Medical Envista PROCEPT BioRobotics iRhythm Technologies Warby Parker LivaNova Enovis TransMedics Group NovoCure Tandem Diabetes Care Inari Medical (NASDAQ:NARI) and RxSight (NASDAQ:RXST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking. Do analysts rate NARI or RXST? Inari Medical presently has a consensus price target of $68.00, indicating a potential downside of 14.91%. RxSight has a consensus price target of $58.13, indicating a potential upside of 82.21%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than Inari Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inari Medical 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14RxSight 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is NARI or RXST more profitable? Inari Medical has a net margin of -13.68% compared to RxSight's net margin of -23.92%. Inari Medical's return on equity of -10.09% beat RxSight's return on equity.Company Net Margins Return on Equity Return on Assets Inari Medical-13.68% -10.09% -6.60% RxSight -23.92%-14.00%-12.51% Which has more risk and volatility, NARI or RXST? Inari Medical has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Which has better earnings & valuation, NARI or RXST? Inari Medical has higher revenue and earnings than RxSight. Inari Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInari Medical$574.50M8.14-$1.64M-$1.35-59.20RxSight$89.08M14.43-$48.61M-$0.83-38.43 Does the media favor NARI or RXST? In the previous week, Inari Medical had 2 more articles in the media than RxSight. MarketBeat recorded 4 mentions for Inari Medical and 2 mentions for RxSight. RxSight's average media sentiment score of 1.81 beat Inari Medical's score of 0.19 indicating that RxSight is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inari Medical 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community favor NARI or RXST? Inari Medical received 19 more outperform votes than RxSight when rated by MarketBeat users. However, 68.12% of users gave RxSight an outperform vote while only 57.89% of users gave Inari Medical an outperform vote. CompanyUnderperformOutperformInari MedicalOutperform Votes6657.89% Underperform Votes4842.11% RxSightOutperform Votes4768.12% Underperform Votes2231.88% Do institutionals and insiders believe in NARI or RXST? 91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by insiders. Comparatively, 9.4% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryInari Medical and RxSight tied by winning 9 of the 18 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightOphthalmic goods IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$11.14B$5.65B$9.04BDividend YieldN/A1.63%5.31%4.00%P/E Ratio-38.4336.6790.8219.28Price / Sales14.434.961,051.1879.82Price / CashN/A16.0746.0938.87Price / Book7.143.195.135.00Net Income-$48.61M$235.23M$113.24M$222.75M7 Day Performance-4.97%-3.58%-0.68%-0.72%1 Month Performance3.84%-1.82%5.21%4.19%1 Year Performance-36.96%-3.61%25.35%21.73% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight2.9422 of 5 stars$31.90-0.9%$58.13+82.2%-37.2%$1.29B$89.08M-38.43220NARIInari Medical1.6458 of 5 stars$79.86+0.1%$68.00-14.9%+37.8%$4.68B$493.63M-59.161,300NVSTEnvista3.6219 of 5 stars$21.240.0%$20.21-4.9%-8.5%$3.66B$2.51B-3.2712,800Analyst RevisionPRCTPROCEPT BioRobotics3.4448 of 5 stars$69.75+0.3%$97.86+40.3%+31.1%$3.64B$136.19M-35.77430Positive NewsIRTCiRhythm Technologies0.9387 of 5 stars$109.50-0.5%$108.45-1.0%-6.7%$3.43B$560.03M-22.532,000WRBYWarby Parker2.4125 of 5 stars$26.64+1.0%$21.77-18.3%+82.4%$2.71B$669.77M-98.683,491LIVNLivaNova3.4747 of 5 stars$48.51+1.4%$69.17+42.6%-6.0%$2.63B$1.15B115.502,900ENOVEnovis3.3347 of 5 stars$44.45+1.0%$65.86+48.1%-27.5%$2.53B$1.71B-20.306,550Short Interest ↓Positive NewsTMDXTransMedics Group4.2037 of 5 stars$70.24-3.3%$122.70+74.7%-21.0%$2.36B$241.62M74.72210Short Interest ↑NVCRNovoCure3.722 of 5 stars$21.65-2.7%$32.67+50.9%+32.7%$2.34B$509.34M-15.461,453TNDMTandem Diabetes Care4.227 of 5 stars$35.23-2.4%$53.81+52.7%+37.2%$2.31B$747.72M-18.252,400Positive News Related Companies and Tools Related Companies Inari Medical Alternatives Envista Alternatives PROCEPT BioRobotics Alternatives iRhythm Technologies Alternatives Warby Parker Alternatives LivaNova Alternatives Enovis Alternatives TransMedics Group Alternatives NovoCure Alternatives Tandem Diabetes Care Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RXST) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.